OCT1 Antibody

Introduction

The OCT1 antibody is a critical research tool used to detect the transcription factor Oct-1 (POU2F1), a ubiquitously expressed protein involved in regulating gene expression, stem cell maintenance, and cancer progression. This antibody is widely employed in molecular biology techniques such as Western blotting, immunoprecipitation, and chromatin immunoprecipitation (ChIP). Below, we present a detailed analysis of its applications, specifications, and research findings, supported by data from peer-reviewed studies and commercial product information.

Product Overview

• Target Protein: Oct-1 (POU2F1), a transcription factor containing a POU domain with a homeobox subdomain .

• Applications:

  • Western blotting (WB)

  • Immunoprecipitation (IP)

  • Chromatin immunoprecipitation (ChIP) .

Technical Details

Cancer Stem Cell Regulation

• OCT1 antibody has been used to demonstrate Oct-1’s role in maintaining cancer stem cell (CSC) populations. Studies show that high Oct-1 protein levels correlate with ALDH HI (high aldehyde dehydrogenase activity) cells, a CSC marker, in tumors .

• Antibody-mediated knockdown of Oct-1 reduces CSC frequency in breast and lung cancer cell lines .

Hematopoietic Stress Resistance

• In murine models, Oct-1 deletion protects against leukemogenesis but causes bone marrow failure. The antibody has been used to validate Oct-1’s role in hematopoietic stress resistance via 5-fluorouracil (5-FU) sensitivity assays .

Drug Transport Studies

• While the OCT1 antibody targets the transcription factor, unrelated studies on the organic cation transporter OCT1 highlight its role in drug uptake (e.g., metformin, daunorubicin) .

Hepatocellular Carcinoma (HCC)

• Immunohistochemical studies using OCT1 antibodies (head/tail epitopes) reveal that plasma membrane localization of Oct-1 correlates with improved survival in HCC patients treated with sorafenib .

Breast Cancer Prognosis

• Positive Oct-1 immunoreactivity in ER-positive breast cancer tissues is associated with shorter disease-free survival (DFS) .

Antibody Performance in Cancer Studies